- Home
- Companies
- usa washington
- cellular therapy
Refine by
Cellular Therapy Suppliers In Usa Washington
4 companies found
based inSeattle, WASHINGTON (USA)
Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies. Universal Cells edits genes ...
Realizing the potential of pluripotent stem cells requires that the therapeutic cells derived from PSCs be accepted by patients. PSC-derived cells that have not been engineered to avoid allogeneic rejection will be eliminated soon after ...
based inSeattle, WASHINGTON (USA)
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of ...
Custom Assay Development to Advance Molecules. You need reliable approaches to support what’s next in your development programs whether they are complex small molecules, advanced biologics, or vaccines. At Nexelis, a Q² Solutions Company, ...
based inBothell, WASHINGTON (USA)
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics (using mammalian and microbial systems), mRNA, pDNA, viral vector and cell therapy products, from ...
AGC Biologics develops and manufactures diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open ...
based inSeattle, WASHINGTON (USA)
window into the adaptive immune system the world hadn’t thought possible. Together, Harlan and his brother Chad, founded Adaptive to meet the worldwide demand for immunosequencing technology. Over the past decade, we have developed our proprietary ...
We are currently leveraging our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of ...